Introduction: new insight into understanding the relation of type 2 diabetes mellitus, insulin resistance, and cardiovascular disease

2003 ◽  
Vol 92 (4) ◽  
pp. 1-2 ◽  
Author(s):  
Willa A. Hsueh
2020 ◽  
Vol 52 (10) ◽  
pp. 695-707
Author(s):  
Emilio Antonio Francischetti ◽  
Rômulo Sperduto Dezonne ◽  
Cláudia Maria Pereira ◽  
Cyro José de Moraes Martins ◽  
Bruno Miguel Jorge Celoria ◽  
...  

AbstractIn 2016, the World Health Organization estimated that more than 1.9 billion adults were overweight or obese. This impressive number shows that weight excess is pandemic. Overweight and obesity are closely associated with a high risk of comorbidities, such as insulin resistance and its most important outcomes, including metabolic syndrome, type 2 diabetes mellitus, and cardiovascular disease. Adiponectin has emerged as a salutary adipocytokine, with insulin-sensitizing, anti-inflammatory, and cardiovascular protective properties. However, under metabolically unfavorable conditions, visceral adipose tissue-derived inflammatory cytokines might reduce the transcription of the adiponectin gene and consequently its circulating levels. Low circulating levels of adiponectin are negatively associated with various conditions, such as insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. In contrast, several recent clinical trials and meta-analyses have reported high circulating adiponectin levels positively associated with cardiovascular mortality and all-cause mortality. These results are biologically intriguing and counterintuitive, and came to be termed “the adiponectin paradox”. Adiponectin paradox is frequently associated with adiponectin resistance, a concept related with the downregulation of adiponectin receptors in insulin-resistant states. We review this contradiction between the apparent role of adiponectin as a health promoter and the recent evidence from Mendelian randomization studies indicating that circulating adiponectin levels are an unexpected predictor of increased morbidity and mortality rates in several clinical conditions. We also critically review the therapeutic perspective of synthetic peptide adiponectin receptors agonist that has been postulated as a promising alternative for the treatment of metabolic syndrome and type 2 diabetes mellitus.


2013 ◽  
Vol 2013 ◽  
pp. 1-10
Author(s):  
Nabajyoti Deka ◽  
Swapnil Bajare ◽  
Jessy Anthony ◽  
Amrutha Nair ◽  
Anagha Damre ◽  
...  

Metabolic syndrome is a widely prevalent multifactorial disorder associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic disorder. Thiazolidinediones (TZDs) are potent PPARγ ligand and used as insulin sensitizers in the treatment of type 2 diabetes mellitus. They are potent insulin-sensitizing agents but due to adverse effects like hepatotoxicity, a safer alternative of TZDs is highly demanded. Here we report synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives as an alternate remedy for insulin resistance.


2019 ◽  
Vol 2 (2) ◽  
Author(s):  
Arum Tri Wahyuningsih ◽  
Fuad Anshori ◽  
Elizabeth Henny Herningtyas ◽  
Tri Ratnaningsih

Insulin resistance as a cause of type 2 diabetes mellitus is associated with subclinical inflammatory processes. Insulin resistance with obesity, hypertension, and dyslipidemia contribute to metabolic syndrome that increased risk of cardiovascular disease. High sensitivity C-reactive protein (hs-CRP) is an inflammatory marker that is thought to be associated with both type 2 diabetes mellitus and cardiovascular disease. This study evaluated hs-CRP, HbA1c, and body mass index in a healthy community. This cross-sectional study is an observational analytic study evaluating the association between hs-CRP, HbA1c, and body mass index. The research subjects were all healthy on a community gathering in community service programs, and if there were any signs or symptoms of infection or inflammation, they would be excluded. Measurements of hs-CRP and HbA1c were carried out using the HPLC and ELISA methods, respectively. The measurement results were analyzed to evaluate the characteristics of the subject and assess the relationship between the parameters studied with different mean and correlation tests. In 25 subjects involved, it was found that 96% had an HbA1c value of <6.5% with a normal body mass index of 15 subjects (60%), and the rest were in the category of overweight. The median hs-CRP level was 2.99 mg / L (0.81-13.74 mg / L), with a low heart risk category of only 4% of all study subjects. There was no correlation between hs-CRP with HbA1c (r = 0.35; p = 0.868) and body mass index (r = 0.37; p = 0.069). Only one subject was included in the diabetes diagnostic criteria, but 96% of the study population had hs-CRP, which was included in the medium-risk and high-risk category for heart disease. There was no association between hs-CRP and HbA1c and body mass index in healthy populations in this community.


Sign in / Sign up

Export Citation Format

Share Document